

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

NEOTHERAPEUTICS INC
Form 8-K
December 20, 2001

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES AND EXCHANGE ACT OF 1934

December 20, 2001

Date of Report (Date of earliest event reported)

NEOTHERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

DELAWARE
(State or other Jurisdiction
of Incorporation)

000-28782
(Commission File Number)

93-0979187
(IRS Employer
Identification Number)

157 TECHNOLOGY DRIVE
IRVINE, CALIFORNIA
(Address of principal executive offices)

92618
(Zip Code)

(949) 788-6700
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS.

On December 20, 2001, NeoTherapeutics, Inc. issued a news release announcing that it's subsidiary, NeoGene Technologies, entered into a second license agreement with Pfizer Inc. for the use of an orphan receptor identified by NeoGene. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference.

ITEM 7. EXHIBITS

Exhibits:

99.1 Press Release dated December 20, 2001.

SIGNATURES

Edgar Filing: NEOTHERAPEUTICS INC - Form 8-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEOTHERAPEUTICS, INC.

Date: December 20, 2001

By: /s/ Samuel Gulko

Name: Samuel Gulko

Title: Senior Vice President, Finance,
Chief Financial Officer, Secretary
and Treasurer

Exhibit

Number

Document Description

99.1

Press Release dated December 20, 2001.